1 / 37

STD Surveillance 2001

STD Surveillance 2001. Adapted from CDC by Jill Gallin, CPNP Assistant Professor of Clinical Nursing. The number of disease reported does not equal the incidence. Factors affecting report data. Reporting systems Laboratories Providers Information systems

gefjun
Download Presentation

STD Surveillance 2001

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. STD Surveillance 2001 Adapted from CDC by Jill Gallin, CPNP Assistant Professor of Clinical Nursing

  2. The number of disease reported does not equal the incidence

  3. Factors affecting report data • Reporting systems • Laboratories • Providers • Information systems • Increase or decrease in screening • Sensitivity of diagnostic tests/ Ability to diagnose disease

  4. ChlamydiaSexually Transmitted Disease Surveillance 2001 Division of STD Prevention

  5. Chlamydia — Number of states that require reporting of Chlamydia trachomatis infections: United States, 1987–2001

  6. Chlamydia — Reported rates: United States, 1984–2001

  7. Chlamydia — Rates by state: United States and outlying areas, 2001 Note: The total rate of chlamydia for the United States and outlying areas (including Guam, Puerto Rico and Virgin Islands) was 275.5 per 100,000 population.

  8. Chlamydia — Rates by region: United States, 1984–2001

  9. Chlamydia — Rates by sex: United States, 1984–2001

  10. Chlamydia — Age- and sex-specific rates: United States, 2001

  11. Chlamydia — Trends in positivity among 15-44 year old women tested in family planning clinics by HHS regions, 1988–2001 Note: Trends adjusted for changes in laboratory test method and associated increases in test sensitivity. No data on laboratory test method available for Region VII in 1995 and Regions IV and V in 1996.SOURCE: Regional Infertility Prevention Program; Office of Population Affairs; Local and State STD Control Programs; Centers for Disease Control and Prevention

  12. GonorrheaSexually Transmitted Disease Surveillance 2001 Division of STD Prevention

  13. Gonorrhea — Reported rates: United States, 1970–2001 and the Healthy People year 2010 objective Note: The Healthy People 2010 (HP2010) objective for gonorrhea is 19.0 cases per 100,000 population.

  14. Gonorrhea — Rates by region: United States, 1981–2001 and the Healthy People year 2010 objective

  15. Gonorrhea — Rates by sex: United States, 1981–2001 and the Healthy People year 2010 objective

  16. Gonorrhea — Rates by race and ethnicity: United States, 1981–2001 and the Healthy People year 2010 objective

  17. Gonorrhea — Age- and sex-specific rates: United States, 2001

  18. Gonococcal Isolate Surveillance Project (GISP) — Location of participating clinics and regional laboratories: United States, 2001 Tripler AMC

  19. Gonococcal Isolate Surveillance Project (GISP) — Penicillin and tetracycline resistance among GISP isolates, 2001 Note: PPNG=penicillinase-producing N. gonorrhoeae; TRNG=plasmid-mediated tetracycline resistant N. gonorrhoeae; PPNG-TRNG=plasmid-mediated penicillin and tetracycline resistant N. gonorrhoeae; PenR=chromosomally mediated penicillin resistant N. gonorrhoeae; TetR=chromosomally mediated tetracycline resistant N. gonorrhoeae; CMRNG=chromosomally mediated penicillin and tetracycline resistant N. gonorrhoeae.

  20. Gonococcal Isolate Surveillance Project (GISP) — Percent of Neisseria gonorrhoeae isolates with resistance or intermediate resistance to ciprofloxacin, 1990–2001 Note: Resistant isolates have ciprofloxacin MICs >1 mg/mL. Isolates with intermediate resistance have ciprofloxacin MICs of 0.125 - 0.5 mg/mL. Susceptibility to ciprofloxacin was first measured in GISP in 1990.

  21. SyphilisSexually Transmitted Disease Surveillance 2001 Division of STD Prevention

  22. Syphilis — Reported cases by stage of illness: United States, 1941–2001

  23. Primary and secondary syphilis — Reported rates: United States, 1970–2001 and the Healthy People year 2010 objective Note: The Healthy People 2010 (HP2010) objective for primary and secondary syphilis is 0.2 case per 100,000 population.

  24. Primary and secondary syphilis — Rates by state: United States and outlying areas, 2001 Note: The total rate of primary and secondary syphilis for the United States and outlying areas (including Guam, Puerto Rico and Virgin Islands) was 2.2 per 100,000 population. The Healthy People year 2010 objective is 0.2 per 100,000 population.

  25. Primary and secondary syphilis — Rates by region: United States, 1981–2001 and the Healthy People year 2010 objective

  26. Primary and secondary syphilis — Rates by sex: United States, 1981–2001 and the Healthy People year 2010 objective

  27. Primary and secondary syphilis — Rates by race and ethnicity: United States, 1981–2001 and the Healthy People year 2010 objective

  28. Primary and secondary syphilis — Male to female rate ratios: United States, 1981–2001

  29. Primary and secondary syphilis — Age- and sex-specific rates: United States, 2001

  30. Congenital syphilis — Rates for infants <1 year of age: United States, 1981–2001 and the Healthy People year 2010 objective Note: The Healthy People 2010 (HP2010) objective for primary and secondary syphilis is 0.2 case per 100,000 population. The surveillance case definition for congenital syphilis changed in 1988.

  31. Other Sexually Transmitted DiseasesSexually Transmitted Disease Surveillance 2001 Division of STD Prevention

  32. Chancroid — Reported cases: United States, 1981–2001

  33. Genital herpes — Initial visits to physicians’ offices: United States, 1966–2001 SOURCE: National Disease and Therapeutic Index (IMS America, Ltd.)

  34. Genital herpes simplex virus type 2 infections — Percent seroprevalence according to age in NHANES* II (1976-1980) and NHANES III (1988-1994) Note: Bars indicate 95% confidence intervals. *National Health and Nutrition Examination Survey

  35. Genital warts — Initial visits to physicians’ offices: United States, 1966–2001 SOURCE: National Disease and Therapeutic Index (IMS America, Ltd.)

  36. Nonspecific urethritis — Initial visits to physicians’ offices by men:United States, 1966–2001 SOURCE: National Disease and Therapeutic Index (IMS America, Ltd.)

  37. Trichomonal and other vaginal infections — Initial visits to physicians’ offices: United States, 1966–2001 SOURCE: National Disease and Therapeutic Index (IMS America, Ltd.)

More Related